That exceeds anything achieved by semaglutide or tirzepatide in comparable time frames
A small subset of participants, approximately 12%, continued losing through week 48 without plateauing
retatrutide adds a dose-dependent heart-rate signal and the highest adverse-event burden in indirect analyses
By week 4, the scale had moved again
Given the secondary nature of this study and the number of statistical tests, we did not look at possible clinical/behavioral implications of these endocrine effects a relevant question that was beyond the scope of the present study and should be explored in the future
It is important to note that claims about increased energy expenditure in humans remain insufficiently evidenced at this stage, and the net glycaemic effects reflect observed trial outcomes rather than a straightforward mechanistic reduction in hepatic glucose output the concurrent glucagon receptor agonism may, in fact, influence hepatic glucose production in a complex and not fully characterised manner
